Get the Stockscreener App
1.11
3.74%
0.04
Gt Biopharma Inc stock is traded at $1.11, with a volume of 95,992.
It is up +3.74% in the last 24 hours and down -44.08% over the past month.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
See More
Previous Close:
$1.07
Open:
$1.09
24h Volume:
95,992
Relative Volume:
0.94
Market Cap:
$3.63M
Revenue:
-
Net Income/Loss:
$-9.64M
P/E Ratio:
-0.1603
EPS:
-6.9236
Net Cash Flow:
$-10.11M
1W Performance:
-17.16%
1M Performance:
-44.08%
6M Performance:
-48.37%
1Y Performance:
-48.61%
1-Day Range:
$1.09
$1.15
1-Week Range:
$1.05
$1.5257
52-Week Range:
$0.96
$4.10
Gt Biopharma Inc Stock (GTBP) Company Profile
Name
Gt Biopharma Inc
Sector
Industry
Phone
(800) 304-9888
Address
505 MONTGOMERY STREET, SAN FRANCISCO
Compare GTBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
0.92 | 1.26B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.58 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.53 | 110.24M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1668 | 351.80M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.24 | 0 | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Initiated | ROTH MKM | Buy |
| May-24-21 | Initiated | H.C. Wainwright | Buy |
| Apr-13-21 | Initiated | B. Riley Securities | Buy |
| Mar-17-21 | Initiated | ROTH Capital | Buy |
Gt Biopharma Inc Stock (GTBP) Latest News
Can machine learning forecast GT Biopharma Inc. recoveryPortfolio Gains Summary & Daily Growth Stock Investment Tips - Newser
Pattern recognition hints at GT Biopharma Inc. upsideJuly 2025 Rallies & Detailed Earnings Play Strategies - Newser
Institutional scanner results for GT Biopharma Inc.2025 Price Targets & Safe Entry Zone Tips - Newser
Using data tools to time your GT Biopharma Inc. exitJuly 2025 PreEarnings & Verified Momentum Stock Watchlist - Newser
Can GT Biopharma Inc. recover in the next quarter2025 Macro Impact & Free Safe Capital Growth Stock Tips - Newser
How to interpret RSI for GT Biopharma Inc. stockBull Run & Stock Timing and Entry Methods - Newser
Real time scanner hits for GT Biopharma Inc. explainedGap Down & Verified Stock Trade Ideas - Newser
Smart tools for monitoring GT Biopharma Inc.’s price actionEntry Point & Step-by-Step Swing Trade Plans - Newser
Can GT Biopharma Inc. Outperform Peers After Recent Pullback2025 Buyback Activity & High Yield Stock Recommendations - newsyoung.net
How to build a dashboard for GT Biopharma Inc. stockMarket Activity Summary & Fast Exit/Entry Strategy Plans - Newser
Published on: 2025-08-18 21:57:55 - Newser
GT Biopharma Inc. Stock Lags Behind Sector BenchmarksTrade Volume Report & High Conviction Buy Zone Alerts - beatles.ru
Is GT Biopharma Inc. stock reversal real or fake2025 Macro Impact & AI Powered Market Trend Analysis - Newser
Is GT Biopharma Inc. a candidate for recovery play2025 Dividend Review & Community Shared Stock Ideas - Newser
Is GT Biopharma Inc. stock entering bullish territoryMarket Movers & Verified Technical Signals - Newser
Is it time to cut losses on GT Biopharma Inc.Portfolio Performance Summary & AI Forecasted Entry/Exit Points - Newser
Comparing GT Biopharma Inc. in custom built stock radarsEarnings Risk Report & Detailed Earnings Play Alerts - Newser
Machine Learning Models Forecast GT Biopharma Inc. UptickJuly 2025 Momentum & Verified Technical Trade Signals - metal.it
What makes GT Biopharma Inc. stock attractive to long term investorsWeekly Gains Summary & Long-Term Capital Growth Ideas - Newser
Best data tools to analyze GT Biopharma Inc. stock2025 Volume Leaders & Weekly Return Optimization Alerts - Newser
Using fundamentals and technicals on GT Biopharma Inc.Recession Risk & Long-Term Capital Growth Strategies - Newser
Top chart patterns to watch in GT Biopharma Inc.2025 Price Action Summary & Weekly Stock Performance Updates - Newser
Can volume confirm reversal in GT Biopharma Inc.Quarterly Growth Report & Daily Momentum Trading Reports - Newser
Combining price and volume data for GT Biopharma Inc.Trade Risk Report & Free Long-Term Investment Growth Plans - Newser
GT Biopharma's Q2 2025 Results: Decoding Pipeline Progress and Financial Resilience as Catalysts for Long-Term Outperformance - AInvest
GT Biopharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
GT Biopharma, Inc. Advances GTB-3650 TriKE® Phase 1 Trial and Prepares for GTB-5550 IND Submission by End of 2025 - Quiver Quantitative
GT Biopharma Reports Second Quarter 2025 Financial Results - GlobeNewswire
GT Biopharma's Cancer Drug Shows Progress: Phase 1 Trial Reaches Third Cohort With $5.3M Cash Runway - Stock Titan
GT Biopharma Inc. Sees Relief Buying After Extended DropDay Trade & Technical Pattern Alert System - thegnnews.com
GT Biopharma Inc. Nearing Breakout Level After BounceNew Guidance & Fast Momentum Entry Tips - kangso.co.kr
Advanced analytics toolkit walkthrough for GT Biopharma Inc.July 2025 Spike Watch & Stepwise Trade Signal Implementation - Newser
Pattern Scan Adds GT Biopharma Inc. to Watchlist [July 2025 Spike Watch]AI Enhanced Market Trend Forecasts - 선데이타임즈
Gt Biopharma Inc Stock (GTBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):